ChiCTR1900022830 版本V1.1 版本创建时间2020/10/26 11:47:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900022830 

最近更新日期:

Date of Last Refreshed on:

2020-10-26 11:47:02 

注册时间:

Date of Registration:

2019-04-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

任洪杏医师:请上传伦理审批文件并填写伦理审批日期。 微小斜视的临床观察

Public title:

clinical outcomes of microtropia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

微小斜视的临床观察

Scientific title:

clinical outcomes of microtropia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

任洪杏 

研究负责人:

任洪杏 

Applicant:

Hongxing Ren 

Study leader:

Hongxing Ren 

申请注册联系人电话:

Applicant telephone:

+86 13437156599

研究负责人电话:

Study leader's telephone:

+86 13437156599

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

792206198@qq.com

研究负责人电子邮件:

Study leader's E-mail:

792206198@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国湖北省武汉市汉阳区琴断口街办事处罗七北路12号金龙公馆写字楼

研究负责人通讯地址:

中国湖北省武汉市汉阳区琴断口街办事处罗七北路12号金龙公馆写字楼

Applicant address:

Jinlong Plaza, 12 Luoqi Road North, Qin-Duan-Kou Street, Hanyang District, Hubei, China

Study leader's address:

Jinlong Plaza, 12 Luoqi Road North, Qin-Duan-Kou Street, Hanyang District, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

武汉爱尔眼科汉阳医院

Applicant's institution:

Wuhan Aier Eye Hospital (Hanyang)

研究负责人所在单位:

武汉爱尔眼科汉阳医院

Affiliation of the Leader:

Wuhan Aier Eye Hospital (Hanyang)

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HYEYE2019IRB02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

武汉爱尔眼科汉阳医院伦理委员会

Name of the ethic committee:

Ethic Committee of Wuhan Aier Eye Hospital (Hanyang)

伦理委员会批准日期:

Date of approved by ethic committee:

2019-04-11 00:00:00

伦理委员会联系人:

柳婉依

Contact Name of the ethic committee:

Wanyi Liu

伦理委员会联系地址:

中国湖北省武汉市汉阳区琴断口街办事处罗七北路12号金龙公馆写字楼武汉爱尔眼科汉阳医院

Contact Address of the ethic committee:

Wuhan Aier Eye Hospital (Hanyang), 12 Luoqi Road North, Qin-Duan-Kou Street, Hanyang District, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国湖北省武汉市武汉爱尔眼科汉阳医院

Primary sponsor:

Wuhan Aier Eye Hospital (Hanyang), Wuhan, Hubei Province, China

研究实施负责(组长)单位地址:

中国湖北省武汉市汉阳区琴断口街办事处罗七北路12号金龙公馆写字楼

Primary sponsor's address:

Jinlong Plaza, 12 Luoqi Road North, Qin-Duan-Kou Street, Hanyang District, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

Country:

China

Province:

hubei

City:

单位(医院):

武汉爱尔眼科汉阳医院

具体地址:

中国湖北省武汉市武汉爱尔眼科汉阳医院

Institution
hospital:

Wuhan Aier Eye Hospital (Hanyang)

Address:

Jinlong Plaza, 12 Luoqi Road North, Qin-Duan-Kou Street, Hanyang District, Hubei, China

经费或物资来源:

爱尔眼科集团资助

Source(s) of funding:

group funding of aier

Target disease:

microtropia

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

利用现代仪器,如OCT、多焦电生理、视野等手段配合以往传统的检查,可能让我们对微小斜视有一个更全面的了解,以期区分不同类型的微小斜视的临床特点,进而为寻找病因以及有针对性的治疗提供帮助。  

Objectives of Study:

Using modern instruments, such as OCT, multi-focal electrophysiology, visual field and other means to cooperate with traditional examinations, may give us a more comprehensive understanding of microtropia, in order to distinguish the clinical characteristics of different types of micro-strabismus, and then to find the cause and Targeted treatments help.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

拟计划收集于2018年-2021年我院小儿眼科门诊就诊的诊断为微小斜视患者20例以上

Inclusion criteria

It is planned to collect more than 20 patients with microtropia diagnosed in the pediatric ophthalmology clinic of our hospital from 2018 to 2021.

排除标准:

屈光间质中重度混浊,眼底器质性病变,其他类型斜视、不能配合检查者。

Exclusion criteria:

Refractive interstitial medium turbidity, fundus organic lesions, other types of strabismus, can not cooperate with the examiner.

研究实施时间:

Study execute time:

From 2019-05-01 00:00:00 To 2020-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-05-01 00:00:00 To 2020-05-01 00:00:00  

干预措施:

Interventions:

组别:

微小斜视组

样本量:

20

Group:

microtropia

Sample size:

干预措施:

oct 、ERG、 视野、 VEP 及传统检查

干预措施代码:

Intervention:

oct, ERG, vision field, VEP and traditional measurements

Intervention code:

组别:

正常对照组

样本量:

20

Group:

normal control

Sample size:

干预措施:

oct 、ERG、 视野、 VEP 及传统检查

干预措施代码:

Intervention:

oct, ERG, vision field, VEP and traditional measurements

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

武汉爱尔眼科汉阳医院 

单位级别:

三甲医院 

Institution
hospital:

Wuhan Aier Eye Hospital (Hanyang)

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

注视偏中心距离

指标类型:

主要指标

Outcome:

Gaze off the center distance

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

fmERG反应振幅密度

指标类型:

主要指标

Outcome:

fmERG response densities

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

vep 振幅和潜伏期

指标类型:

主要指标

Outcome:

Vep amplitude and latency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视野固视丢失率,PSD, MD

指标类型:

主要指标

Outcome:

Vision fixation loss rate, PSD, MD

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

人眼检查数据

组织:

Sample Name:

Human eye inspection data

Tissue:

人体标本去向

其它  

说明

无创伤

Fate of sample:

0thers  

Note:

Atraumatic

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 4 years
最大 Max age 不限 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

所有受试者均采用相同检查方法

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Chinese clinical trial registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据统计表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-04-27 12:19:34